ARA-290
Also Known As: Cibinetide, ARA290, ARA-290 peptide, Non-hematopoietic EPO peptide, Tissue-protective peptide EPO, Innate repair receptor agonist, EPO-derived peptide, Cibinetide ARA-290, Small-fiber neuropathy peptide, Sarcoidosis neuropathy peptide, EPO analog non-hematopoietic, erythropoietin derivative
ARA-290 is a research-grade Non-hematopoietic EPO-derived 11-amino acid cyclic peptide targeting Innate repair receptor studied in Immunity & Wellness research. It is supplied strictly for in vitro laboratory research use only - not for human or animal consumption, and not FDA-approved.
Evidence Tier: Investigational - In active human clinical trials; not yet approved.
An EPO-derived peptide studied for nerve repair and neuropathic pain without the blood-thickening risk of EPO.
At A Glance
| Category | Immunity & Wellness |
|---|---|
| Compound Class | Non-hematopoietic EPO-derived 11-amino acid cyclic peptide; innate repair receptor agonist |
| Molecular Target | Innate repair receptor (IRR = EPO-R + CD131 beta-common heterodimer); tissue-protective signaling without erythropoiesis; anti-apoptotic and anti-inflammatory |
| Molecular Weight | 1257.4 Da |
| Amino Acid Sequence | QEQLERALNSS |
| CAS Number | 1208243-50-8 |
| Half-Life | ~2 minutes |
| WADA Status | not_listed |
| Evidence Tier | Investigational |
Mechanism Of Action
It connects to a specific "repair switch" on your cells that normally responds to damage. When connected, it turns off inflammation signals and tells the nerve tissue to rebuild itself.
Studied For
- Small-fiber neuropathy (sarcoidosis, diabetes)
- Neuropathic pain research
- Tissue-injury repair
- Diabetic neuropathy models
- Sarcoidosis-related neuropathy
- Corneal nerve fiber regeneration
- Immune modulation
- Anti-inflammatory
- Sepsis models
- Cardiac ischemia protection
- Renal protection
- Obesity metabolic improvement
- Beta-cell protection in diabetes
- Wound healing acceleration
- neuropathy
- nerve pain
- anti-inflammatory
- tissue repair
- small fiber neuropathy
- sarcoidosis
- diabetic neuropathy
Reported Research Findings
Multiple Phase 2 trials, including a controlled sarcoidosis small-fiber neuropathy study, reported pain relief and improved corneal nerve-fiber measures. Early-phase but rigorously controlled.
Safety And Handling Notes
Reported well tolerated; designed to avoid the blood-thickening effects of erythropoietin.
Investigational with FDA orphan designation; no completed Phase 3. Anti-doping status is unresolved: not named on the WADA 2026 List, but the S2.1.5 innate repair receptor agonist category is open-ended. Research use only.
Regulatory Status
Investigational; FDA orphan designation; not marketed. Not named on the WADA 2026 Prohibited List, but as an erythropoietin-derived innate repair receptor agonist it may fall within S2.1.5, whose examples (asialo EPO, carbamylated EPO) are explicitly non-exhaustive. Competitive athletes should treat its status as unresolved and verify with their anti-doping organization.
Full Reference Detail
Related Research Guides
Maintained By The Pep Nation Lab Research Team. See Our Editorial Standards And Research Methodology For How This Reference Is Sourced And Reviewed.
This Reference Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption. See The Full Research Disclaimer.